9
panel
FasterCures Private Dinner (Invite only)
landing page
Achieving Health Equity and Diversity in Clinical Trials
The underrepresentation of diverse groups in clinical research, mistrust in research, and the lack o
f diversity in the health workforce play significant roles in the persistence of health inequities.
+ Read More
landing page
Changemakers
What is the power of philanthropy to disrupt the biomedical innovation ecosystem?, Members are Guide
d by the Following Statement of Purpose
We are a collective of philanthropic innovators that have come together to:, FasterCures’ Changemakers Members
Jeff Allen, CEO, Friends of Cancer Research
Margaret Anderson, Managing Director, Deloitte (FasterCures Board Liaison)
+ Read More
report
The Current Landscape of the Science of Patient Input
In the last decade, FasterCures and many stakeholders across the biomedical research ecosystem have
driven initiatives to ensure that patients’ perspectives and input are appropriately represented across the product-development continuum and post-approv
+ Read More
panel
UAE Medical Research and Health System Site Visit (Invite only)
A small delegation of leading health experts from the FasterCures board and MENA Summit will tou
r institutions in Abu Dhabi to expand participants' understanding of UAE investments in health and biomedical research.
+ Read More
video
Research Roadmaps: A Case Study in Charting a Path Forward to Accelerate Breakthrough Cures
Setting specific objectives and establishing strategies geared toward progressing treatments and c
ures is a critical, yet sometimes difficult, task for patient organizations.
+ Read More
article
Does it Work for Patients? A Multi-Step Approach to Defining Performance and Measuring Progress Across the Biomedical Ecosystem
Quick Links
Step One: Discover Existing Research »
Step Two: Articulate Ideals»
Step Three: Ident
ify Measures »
+ Read More
article
Patient Organizations as Research and Data Partners
What data assets are patient organizations creating, and how are they adding value to the work of pa
rtners trying to accelerate therapeutic development for patients?
+ Read More
article
Pediatric Biomarkers: A Slow Zone for Patients
Q. When it comes to oncology, what is one specific example of how the system is not performing well
for patients, in other words, a Slow Zone?
+ Read More